GABAergic Drugs for the Treatment of Migraine

Author(s): Anja Puppe, Volker Limmroth

Journal Name: CNS & Neurological Disorders - Drug Targets
(Formerly Current Drug Targets - CNS & Neurological Disorders)

Volume 6 , Issue 4 , 2007

Become EABM
Become Reviewer


Within the last decades significant progress has been made in the understanding of the underlying pathophysiological mechanisms of migraine. There is a general agreement now that migraine is not only a vascular phenomenon but also a genetically determined heterogenic ion-channelopathy resulting in cortical-spreading-depression-like events, the temporary impairment of antinociceptive structures of the brainstem and the activation of the trigeminal-vascular system. The development and use of drugs targeting ion-channels and subsequently reducing cortical excitability appears as a promising avenue for both the acute treatment of migraine and migraine prevention. This review summarizes the current knowledge and evidence for GABAergic drugs in the treatment of migraine.

Keywords: GABA transaminase, Topiramate, Valproic acid, Gabapentin, pregabalin

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [247 - 250]
Pages: 4
DOI: 10.2174/187152707781387305
Price: $65

Article Metrics

PDF: 9